Published in J Mol Cell Cardiol on March 06, 2015
Troponin T-release associates with cardiac radiation doses during adjuvant left-sided breast cancer radiotherapy. Radiat Oncol (2015) 0.90
So! What's aging? Is cardiovascular aging a disease? J Mol Cell Cardiol (2015) 0.88
Impact of cocoa flavanol intake on age-dependent vascular stiffness in healthy men: a randomized, controlled, double-masked trial. Age (Dordr) (2015) 0.81
Mitochondria and oxidative stress in heart aging. Age (Dordr) (2016) 0.79
Mast Cell Inhibition Attenuates Cardiac Remodeling and Diastolic Dysfunction in Middle-aged, Ovariectomized Fischer 344 × Brown Norway Rats. J Cardiovasc Pharmacol (2016) 0.79
Patterns of scheduled follow-up appointments following hospitalization for heart failure: insights from an urban medical center in the United States. Clin Interv Aging (2016) 0.77
Effect of Age, Estrogen Status, and Late-Life GPER Activation on Cardiac Structure and Function in the Fischer344×Brown Norway Female Rat. J Gerontol A Biol Sci Med Sci (2016) 0.77
Pathophysiology of heart failure and frailty: a common inflammatory origin? Aging Cell (2017) 0.75
Exercise Intolerance In Heart Failure With Preserved Ejection Fraction. Methodist Debakey Cardiovasc J (2016) 0.75
Heart failure in older adults: embracing complexity. J Geriatr Cardiol (2016) 0.75
Endothelial specific SIRT3 deletion impairs glycolysis and angiogenesis and causes diastolic dysfunction. J Mol Cell Cardiol (2017) 0.75
Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction. Front Endocrinol (Lausanne) (2017) 0.75
Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunction. JCI Insight (2017) 0.75
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med (2006) 17.13
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature (2004) 11.59
Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med (2006) 10.58
Ribo-gnome: the big world of small RNAs. Science (2005) 10.10
Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med (2008) 9.62
Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci (2000) 8.26
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med (2004) 8.12
RNAi-mediated gene silencing in non-human primates. Nature (2006) 7.60
Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med (1999) 7.59
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet (2012) 6.42
Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc (2011) 5.96
Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med (2000) 5.90
MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res (2007) 5.65
Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol (2000) 5.59
Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol (1999) 5.43
A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol (2013) 5.04
New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation (2002) 4.96
The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med (2001) 4.94
NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res (2005) 4.66
Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation (2000) 4.63
Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet (2011) 4.59
Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation (2003) 4.51
Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation (2003) 4.43
The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res (2006) 4.38
Regular aerobic exercise prevents and restores age-related declines in endothelium-dependent vasodilation in healthy men. Circulation (2000) 4.32
Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol (2005) 4.26
Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol (2009) 4.16
The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J (2006) 4.10
Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA (2002) 4.06
MicroRNA-34a regulates cardiac ageing and function. Nature (2013) 4.03
Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol (2007) 3.92
Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med (2007) 3.92
Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation (2007) 3.78
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet (2012) 3.66
Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol (2010) 3.63
Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation (2003) 3.62
Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J (2010) 3.62
Mitochondrial point mutations do not limit the natural lifespan of mice. Nat Genet (2007) 3.53
Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation (2011) 3.48
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation (2006) 3.40
Wasting as independent risk factor for mortality in chronic heart failure. Lancet (1997) 3.37
Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation (2005) 3.34
Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol (1991) 3.30
The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail (2005) 3.26
Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation (2002) 3.20
Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol (2011) 3.19
Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol (2001) 3.18
Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol (2011) 3.13
Myocardial structure and function differ in systolic and diastolic heart failure. Circulation (2006) 3.11
Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation (2006) 3.01
Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail (2010) 3.01
Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ Res (2011) 2.99
Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J (2007) 2.99
The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J (2011) 2.97
Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol (2013) 2.95
Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol (2001) 2.93
Epidemiology of heart failure. Circ Res (2013) 2.84
Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation (2014) 2.79
DNA deletions and clonal mutations drive premature aging in mitochondrial mutator mice. Nat Genet (2008) 2.77
Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation (2009) 2.70
The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J Am Coll Cardiol (2009) 2.61
Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol (2006) 2.61
What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J Am Coll Cardiol (2012) 2.60
Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol (2012) 2.56
Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res (2002) 2.56
Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail (2009) 2.51
Gender differences and aging: effects on the human heart. J Am Coll Cardiol (1995) 2.49
Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol (2010) 2.43
Right ventricular function in heart failure with preserved ejection fraction: a community-based study. Circulation (2014) 2.43
Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol (2012) 2.41
Mitochondrial targeted antioxidant Peptide ameliorates hypertensive cardiomyopathy. J Am Coll Cardiol (2011) 2.40
Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction. J Am Coll Cardiol (2010) 2.37
Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol (2010) 2.35
Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol (2009) 2.34
Left atrial function in diastolic heart failure. Circ Cardiovasc Imaging (2009) 2.34
Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail (2014) 2.30
Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the Cardiovascular Health Study. J Am Coll Cardiol (2007) 2.30
Age-associated cardiovascular changes in health: impact on cardiovascular disease in older persons. Heart Fail Rev (2002) 2.29
Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. Circ Heart Fail (2012) 2.26
Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol (2013) 2.24
From bedside to bench: research agenda for frailty. Sci Aging Knowledge Environ (2005) 2.19
Age and gender influence muscle sympathetic nerve activity at rest in healthy humans. Hypertension (1993) 2.19
Regulation of stroke volume during submaximal and maximal upright exercise in normal man. Circ Res (1986) 2.15
Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation (2012) 2.14
Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol (2009) 2.14
Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res (2013) 2.12
Chronotropic incompetence and its contribution to exercise intolerance in older heart failure patients. J Cardiopulm Rehabil (2006) 2.10
Progression of systolic abnormalities in patients with "isolated" diastolic heart failure and diastolic dysfunction. Circulation (2002) 2.09
Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol (1997) 2.08
Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. Circulation (1990) 2.06